CN Patent

CN1870984A — 1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途

Assigned to Merz Pharma GmbH and Co KGaA · Expires 2006-11-29 · 19y expired

What this patent protects

本发明涉及NMDA受体拮抗剂例如1－氨基环己烷衍生物用于调节淀粉样病变中具有潜在毒性和原纤维生成Aβ肽的沉积的用途。具体地说，本发明涉及美金刚干扰APP加工和降低原纤维生成Aβ肽水平的能力。

USPTO Abstract

本发明涉及NMDA受体拮抗剂例如1－氨基环己烷衍生物用于调节淀粉样病变中具有潜在毒性和原纤维生成Aβ肽的沉积的用途。具体地说，本发明涉及美金刚干扰APP加工和降低原纤维生成Aβ肽水平的能力。

Drugs covered by this patent

amantadine-hydrochloride (AMANTADINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN1870984A
Jurisdiction: CN
Classification: —
Expires: 2006-11-29
Drug substance claim: No
Drug product claim: No
Assignee: Merz Pharma GmbH and Co KGaA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.